| Disclaimer
All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will
or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs.
Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about
future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and
many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this
presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without
limitation, our ability to successfully commercialize our iDose TR therapy; the impact of general macroeconomic conditions including foreign currency fluctuations and future
health crises on our business; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the
occurrence of a crippling accident, natural disaster, or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations;
securing or maintaining adequate coverage or reimbursement by government or third-party payors for procedures using the iStent®, the iStent inject® W, iAccess, iPRIME,
iStent infinite, iDose® TR, our corneal cross-linking products or other products in development, and our compliance with the requirements of participation in federal
healthcare programs such as Medicare and Medicaid; our ability to properly train, and gain acceptance and trust from, ophthalmic surgeons in the use of our products; our
compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and
expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious
safety issues with our products and the uncertainty of patient outcomes; our ability to protect our information systems against cyber threats and cybersecurity incidents, and
to comply with state, federal and foreign data privacy laws and regulations; our ability to protect, and the expense and time-consuming nature of protecting, our intellectual
property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any
related litigation; and our ability to service our indebtedness.
These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange
Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the SEC on November 5, 2024. Our filings
with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products
is available on our website at www.glaukos.com. All forward-looking statements included in this presentation are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this presentation, which speak only as of the date hereof. We do
not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as
may be required under applicable securities law.
© 2024 Glaukos Corporation 2 |
